477 related articles for article (PubMed ID: 19136289)
1. Understanding transmitted HIV resistance through the experience in the USA.
Taiwo B
Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
[TBL] [Abstract][Full Text] [Related]
2. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
Narciso P; Lazzarin A
Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
[TBL] [Abstract][Full Text] [Related]
3. Primary drug resistance in antiretroviral-naïve injection drug users.
Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
[TBL] [Abstract][Full Text] [Related]
4. Current insights into reverse transcriptase inhibitor-associated resistance.
Wainberg MA; White AJ
Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
[No Abstract] [Full Text] [Related]
5. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
Chaix ML; Descamps D; Wirden M; Bocket L; Delaugerre C; Tamalet C; Schneider V; Izopet J; Masquelier B; Rouzioux C; Meyer L; Costagliola D; ; ;
AIDS; 2009 Mar; 23(6):717-24. PubMed ID: 19279445
[TBL] [Abstract][Full Text] [Related]
6. Differences between semen and plasma of nucleoside reverse transcriptase resistance mutations in HIV-infected patients, using a rapid assay.
Liuzzi G; Chirianni A; Zaccarelli M; Zinzi D; Esposito V; Guadagnino V; Antinori A; Piazza M
In Vivo; 2004; 18(4):509-12. PubMed ID: 15369193
[TBL] [Abstract][Full Text] [Related]
7. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
[TBL] [Abstract][Full Text] [Related]
8. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
9. Updated European recommendations for the clinical use of HIV drug resistance testing.
Vandamme AM; Sönnerborg A; Ait-Khaled M; Albert J; Asjo B; Bacheler L; Banhegyi D; Boucher C; Brun-Vézinet F; Camacho R; Clevenbergh P; Clumeck N; Dedes N; De Luca A; Doerr HW; Faudon JL; Gatti G; Gerstoft J; Hall WW; Hatzakis A; Hellmann N; Horban A; Lundgren JD; Kempf D; Miller M; Miller V; Myers TW; Nielsen C; Opravil M; Palmisano L; Perno CF; Phillips A; Pillay D; Pumarola T; Ruiz L; Salminen M; Schapiro J; Schmidt B; Schmit JC; Schuurman R; Shulse E; Soriano V; Staszewski S; Vella S; Youle M; Ziermann R; Perrin L
Antivir Ther; 2004 Dec; 9(6):829-48. PubMed ID: 15651743
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of transmitted resistance to antiretroviral drug classes among young children in the Western Cape Province of South Africa.
van Zyl GU; Cotton MF; Claassen M; Abrahams C; Preiser W
Pediatr Infect Dis J; 2010 Apr; 29(4):370-1. PubMed ID: 19935449
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of resistance testing.
Stebbing J; Gazzard BG
J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
[No Abstract] [Full Text] [Related]
12. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD
Clin Infect Dis; 2008 Jul; 47(2):266-85. PubMed ID: 18549313
[TBL] [Abstract][Full Text] [Related]
13. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
14. Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections.
Taylor S; Sadiq ST; Weller I; Kaye S; Workman J; Cane PA; Bennett J; Copas AJ; Drake SM; Pillay D
Antivir Ther; 2003 Oct; 8(5):479-83. PubMed ID: 14640396
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.
Weinstock HS; Zaidi I; Heneine W; Bennett D; Garcia-Lerma JG; Douglas JM; LaLota M; Dickinson G; Schwarcz S; Torian L; Wendell D; Paul S; Goza GA; Ruiz J; Boyett B; Kaplan JE
J Infect Dis; 2004 Jun; 189(12):2174-80. PubMed ID: 15181563
[TBL] [Abstract][Full Text] [Related]
16. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa.
Barth RE; Wensing AM; Tempelman HA; Moraba R; Schuurman R; Hoepelman AI
AIDS; 2008 Oct; 22(16):2210-2. PubMed ID: 18832885
[TBL] [Abstract][Full Text] [Related]
17. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
19. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.
Yerly S; von Wyl V; Ledergerber B; Böni J; Schüpbach J; Bürgisser P; Klimkait T; Rickenbach M; Kaiser L; Günthard HF; Perrin L;
AIDS; 2007 Oct; 21(16):2223-9. PubMed ID: 18090050
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
Wirden M; Lambert-Niclot S; Marcelin AG; Schneider L; Ait-Mohand H; Brunet C; Angleraud F; Amard S; Katlama C; Calvez V
AIDS; 2009 Jan; 23(1):95-9. PubMed ID: 19050391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
